NEROFE
An Open-Label Phase 1b Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 18 patients (estimated)
- Sponsors
- Immune System Key Ltd
- Collaborators
- Sylvester Comprehensive Cancer Center (Main)
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1595
- NCT Identifier
- NCT04365179
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.